Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.

[1]  V. Fuster,et al.  Guide to Anticoagulant Therapy: Heparin: A Statement for Healthcare Professionals From the American Heart Association , 2001, Circulation.

[2]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[3]  H. Weisman,et al.  Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. , 1998, Circulation.

[4]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[5]  H. Weisman,et al.  Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. , 1997, Circulation.

[6]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[7]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[8]  B. Coller.  Perspectives Series: Cell Adhesion in Vascular Biology Platelet Gpiib/iiia Antagonists: the First Anti-integrin Receptor Therapeutics , 2022 .

[9]  R. Califf,et al.  Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. , 1997, The American journal of cardiology.

[10]  H. Hemker,et al.  Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". , 1996, The Journal of clinical investigation.

[11]  D. S. Neblock,et al.  Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. , 1996, Blood.

[12]  H. Weisman,et al.  Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. , 1995, Journal of the American College of Cardiology.

[13]  M. Horton.  Adhesion Receptors as Therapeutic Targets , 1995 .

[14]  E. Topol,et al.  Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. , 1995, The New England journal of medicine.

[15]  R. Califf,et al.  Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial) , 1995 .

[16]  R. Califf,et al.  Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. , 1994, Circulation.

[17]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[18]  V. Fuster,et al.  Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. , 1994, Circulation.

[19]  D. Waters,et al.  Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.

[20]  L. Wallentin,et al.  Influence on Platelet Function by Heparin in Men with Unstable Coronary Artery Disease , 1991, Thrombosis and Haemostasis.

[21]  V. Wheaton,et al.  Domains specifying thrombin–receptor interaction , 1991, Nature.

[22]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[23]  M. Horne,et al.  Heparin binding to resting and activated platelets. , 1989, Blood.

[24]  F. Loop,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.

[25]  M. Sobel,et al.  Characterization of platelet binding of heparins and other glycosaminoglycans. , 1988, Thrombosis research.

[26]  G. Gogstad,et al.  Heparin‐binding platelet proteins demonstrated by crossed affinity immunoelectrophoresis , 1983, British journal of haematology.

[27]  S. Mohammad,et al.  Effects of heparin on platelet aggregation and release and thromboxane A2 production. , 1981, The American journal of pathology.

[28]  R. Rosenberg,et al.  Effect of heparin and heparin fractions on platelet aggregation. , 1980, The Journal of clinical investigation.

[29]  C. Forbes,et al.  The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. , 1973, Clinical science and molecular medicine.

[30]  C. Eika.  The platelet aggregating effect of eight commercial heparins. , 2009, Scandinavian journal of haematology.

[31]  C. Eika.  On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. , 2009, Scandinavian journal of haematology.

[32]  C. Eika.  Inhibition of thrombin induced aggregation of human platelets by heparin. , 2009, Scandinavian journal of haematology.

[33]  G. Born,et al.  Effects of the Numbers and Sizes of Platelet Aggregates on the Optical Density of Plasma , 1967, Nature.

[34]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.